David Kirn, 4D Molecular Therapeutics CEO (via website)

FDA places hold on 4D Mol­e­c­u­lar’s Fab­ry gene ther­a­py

4D Mol­e­c­u­lar Ther­a­peu­tics qui­et­ly tucked an FDA clin­i­cal hold on its Fab­ry gene ther­a­py in­to an SEC fil­ing.

Mean­while, the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.